RecruitingNot ApplicableNCT04225520

AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT

Assessment of MEchaNical Dyssynchrony as Selection Criterion for Cardiac Resynchronization Therapy


Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

700 participants

Start Date

Dec 10, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Previous experience with cardiac resynchronization therapy (CRT) candidates suggests that selection of these patients can be improved. Current clinical guideline approaches are mainly too unspecific and lead to a high non-responder rate of 30-40%, which causes a burden on health care systems and puts patients at risk of an unnecessary treatment who might benefit more from a conservative approach. Previous work indicated that using the assessment of mechanical dyssynchrony on echocardiography can lower the non-responder rate at least by 50% without compromising sensitivity for detecting amendable patients. The current prospective, randomized, multi-center trial was therefore designed to prove that the characterization of the mechanical properties of the left ventricle can improve patient selection for CRT. Patients will be randomized into one of two study arms: a control study arm with treatment recommendation based on clinical guidelines criteria, or an experimental study arm with treatment recommendation based on the presence of mechanical dyssynchrony. All patients will receive a CRT implantation. In the control study arm, bi-ventricular pacing will be turned on. In the experimental study arm, bi-ventricular pacing will be turned on or off, depending on the presence or absence of mechanical dyssynchrony, respectively. The primary endpoint will be non-inferiority in outcome of a treatment recommendation based on mechanical dyssynchrony, achieved with a lower number of CRT devices implanted, effectively leading to a lower number needed to treat. Outcome measures are the average relative change in continuously measured LVESV per arm and the percentage 'worsened' according to the Packer Clinical Composite Score per arm after 1 year follow-up.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patient has a LVEF ≤ 35%
  • Patient has a LVEDD ≥ 2.7cm/m² or LVEDD ≥ 50mm (m) and ≥45mm (f)
  • Patient has been in a stable medical condition for ≥ 1 month prior inclusion
  • Patient underwent complete revascularization in case of ischemia
  • Patients is able to understand and willing to provide a written informed consent
  • Patient is 18 years or older

Exclusion Criteria17

  • Patients with the following conditions will be excluded:
  • unreliable left ventricular volume measurements
  • severe MR or more than moderate other valvular disease
  • pulmonary hypertension, other than secondary to left heart disease
  • patient on hemodialysis
  • life expectancy \< 1 year
  • pregnant or breastfeeding
  • Patients with prior right ventricular pacing between 20% to 80% will be excluded.
  • Patients with prior right ventricular pacing ≤ 20% or no pacemaker / ICD will be excluded if they have any of the following criteria:
  • PR duration \> 250ms
  • second / third degree atrioventricular block
  • intrinsic QRS duration \< 130ms
  • atrial fibrillation with resting HR \< 50/min or \> 80/min
  • Patients with prior right ventricular pacing ≥ 80% will be excluded if they have any of the following criteria:
  • sensed AV delay \> 250ms
  • paced AV delay \> 280ms
  • Patients with a prior pacemaker / ICD scheduled for LBBaP will be excluded regardless of pacing percentage

Interventions

DEVICECardiac resynchronization therapy ON

Implantation of a CRT device. Bi-ventricular pacing will be turned ON.

DEVICECardiac resynchronization therapy OFF

Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.


Locations(24)

University Hospital Antwerp

Antwerp, Belgium

ZNA Middelheim

Antwerp, Belgium

AZ Sint-Jan Brugge

Bruges, Belgium

AZ Maria Middelares

Ghent, Belgium

Ghent University Hospital

Ghent, Belgium

UZ Leuven

Leuven, Belgium

AZ Damiaan

Ostend, Belgium

AZ Delta

Roeselare, Belgium

Dante Pazzanese Institute of Cardiology

São Paulo, Brazil

CHRU Brest

Brest, France

Groupements des hôpitaux de l'institut catholique de Lille

Lille, France

CHU Rennes - Pontchaillou Hospital

Rennes, France

St. Vinzenz-Hospital

Cologne, Germany

Universitätsmedizin Rostock

Rostock, Germany

Universitätsklinikum Würzburg

Würzburg, Germany

Semmelweis University Heart Center

Budapest, Hungary

Paul Stradins Clinical University hospital

Riga, Latvia

Poznan University of Medical Sciences

Poznan, Poland

Klinika Wad Wrodzonych Serca

Warsaw, Poland

Silesian Center for Heart Diseases

Zabrze, Poland

CHU de São João

Porto, Portugal

Heart Institute Nicolae Stancioiu

Cluj-Napoca, Romania

Hospital Clínico de Barcelona

Barcelona, Spain

Universitätsspital Zürich

Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04225520


Related Trials